GRK2 and familial dilated cardiomyopathy: LVAD therapy significantly lowered these increased GRK2 expression levels (1.28 ± 0.68 vs. 1.58 ± 0.64, P = 0.025) predominantly in DCM patients and in those treated by LVAD for a longer time (see Fig. 7).